{"id":48791,"date":"2025-04-15T10:02:31","date_gmt":"2025-04-15T08:02:31","guid":{"rendered":"https:\/\/www.maiwald.eu\/presseberichte\/cyprumed-enters-license-and-option-agreement-with-msd-for-the-development-of-oral-peptide-therapeutics\/"},"modified":"2025-05-05T10:03:07","modified_gmt":"2025-05-05T08:03:07","slug":"cyprumed-enters-license-and-option-agreement-with-msd-for-the-development-of-oral-peptide-therapeutics","status":"publish","type":"presseberichte","link":"https:\/\/www.maiwald.eu\/cn\/presseberichte\/cyprumed-enters-license-and-option-agreement-with-msd-for-the-development-of-oral-peptide-therapeutics\/","title":{"rendered":"Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics"},"content":{"rendered":"\n<p>Cyprumed GmbH and Merck &amp; Co., Inc. have entered a Non-Exclusive License and Option Agreement to develop oral formulations of peptides using Cyprumed\u2019s drug delivery technology. <\/p>\n\n\n\n<p>MSD gains global non-exclusive rights and options for exclusive licenses on specific targets. Cyprumed may receive up to $493 million in various milestone payments, with potential for more if MSD exercises exclusive options. MSD will handle the development and commercialization of any resulting products. <\/p>\n\n\n\n<p>Both companies expressed enthusiasm, highlighting the collaboration as a validation of Cyprumed\u2019s technology and it&#8217;s importance and a boost for MSD\u2019s peptide pipeline.<\/p>\n\n\n\n<p>This is a summary of an article published by Cyprumed. The full version of the article is available <a href=\"https:\/\/www.cyprumed.net\/press-release\/license-and-option-agreement-with-msd\/\" data-type=\"link\" data-id=\"https:\/\/www.cyprumed.net\/press-release\/license-and-option-agreement-with-msd\/\" target=\"_blank\" rel=\"noopener\">here<\/a>.<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-48791","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/48791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":1,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/48791\/revisions"}],"predecessor-version":[{"id":48794,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/48791\/revisions\/48794"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=48791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}